—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Quest Diagnostics Incorporated (DGX) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for DGX, from the same nightly bakes the boards use. Research diary readings, not advice.

Mentioned on Closelooknet 1 piece · newest: 101, “Sovereign AI: The National Compute Arms Race and Its Investment Map”

Mentioned on Closelooknet

Where DGX appears in the diary — 1 piece, newest first. Every link is our own writing.

101 and glossary

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 0.33 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How DGX has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.33 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Quest Diagnostics Incorporated moved 0.33% on average · correlation 0.13 · higher than 32% of US names
  • Beta, last 3 months 0.35 about the same as over the year
  • On the 10 worst bond days −0.51% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +1.54% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Diagnostics & Research · United States · 8 names with week and year-to-date

Peer group

Diagnostics & Research · United States

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against DGX on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Quest Diagnostics Incorporated

DGX in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Quest Diagnostics runs clinical laboratories and patient service centres across the United States, processing blood, tissue and other samples for hospitals, doctors and insurers. It offers routine and advanced testing in areas such as cancer, infectious disease, drug monitoring and women's health, plus risk-assessment work for life insurers and IT tools that connect results to health systems. It operates under several brands, including AmeriPath and ExamOne, alongside the main Quest Diagnostics name. It is headquartered in Secaucus, New Jersey.
Where it sits in the stack
Quest sits outside our index; it belongs to the diagnostics and research sleeve of the Healthcare sector rather than any layer of the AI build-out.
Who it is priced against
Our peer group carries no comparison for Quest; the market usually names Labcorp as its closest competitor in large-scale clinical laboratory testing.
Why Closelooknet tracks it
Quest holds a seat in the S&P 500 but none in our index, and it carries no Closelooknet score. The one quote that names 'DGX' in the diary refers to Nvidia's DGX Cloud product, not to Quest Diagnostics, so it is a ticker coincidence rather than coverage of the company.
What the diary watches
Whether Quest ever appears in the diary through its own testing volumes rather than through a shared ticker with an unrelated product.

Quest Diagnostics Incorporated (DGX) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 2 analyst actions on the wire · latest: price target by Truist, 2026-09-21

The Street on this name

Analyst actions and the latest print for DGX from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Truist — target 260 from 250 Target raised to $260 from $250 (+5.5% to spot) 2026-09-21
  • Price target UBS — target 245 from 232 Target raised to $245 from $232 (+4% to spot) 2026-09-08

2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst wire → · Earnings wire →

Dividends and capital return trailing yield 1.40%, quarterly · last 0.86 USD on 2026-07-08

Dividends and capital return

What DGX pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 3.32 USD per share · a 1.40% yield on the 2026-09-25 close 4 distributions, paid quarterly 2026-09-25
  • Change on the year +7.0% against the prior twelve months prior twelve months 3.10 USD per share
  • Last distribution 0.86 USD per share as the price series records it, within days of the ex-date 2026-07-08
  • By calendar year 2023: 0.71 USD (partial) · 2024: 2.96 USD · 2025: 3.15 USD · 2026: 2.52 USD to date first distribution recorded in the three-year window: 2023-10-05

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Quest Diagnostics Incorporated (DGX)?

Quest Diagnostics Incorporated trades as DGX on the US exchange (United States) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is DGX in a Closelooknet index?

Not currently — Quest Diagnostics Incorporated is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does DGX trade against its moving averages?

Uptrend stack intact: Trades +0.3% vs the 50-day and +15.7% vs the 200-day average, 5% below the 52-week high and +39.3% off the 52-week low. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Quest Diagnostics Incorporated trade when bond yields rise?

Over the past year Quest Diagnostics Incorporated had a beta of 0.33 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 32% of US names. On the 10 sessions in which long bonds fell most it moved −0.51% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about Quest Diagnostics Incorporated?

Quest Diagnostics Incorporated appears in 1 Closelooknet piece, most recently 101: Sovereign AI: The National Compute Arms Race and Its Investment Map. What Closelooknet said most recently: The investment implications span from NVIDIA (selling DGX Cloud to governments globally) to Nebius (Yandex spin-off building European sovereign cloud) to Dell and HPE (on-premises AI infrastructure for nations with data residency… (101). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

What does Quest Diagnostics Incorporated do?

Quest Diagnostics runs clinical laboratories and patient service centres across the United States, processing blood, tissue and other samples for hospitals, doctors and insurers. It offers routine and advanced testing in areas such as cancer, infectious disease, drug monitoring and women's health, plus risk-assessment work for life insurers and IT tools that connect results to health systems. It operates under several brands, including AmeriPath and ExamOne, alongside the main Quest Diagnostics name. Our peer group carries no comparison for Quest; the market usually names Labcorp as its closest competitor in large-scale clinical laboratory testing.

Where does Quest Diagnostics Incorporated sit in the AI build-out?

Quest sits outside our index; it belongs to the diagnostics and research sleeve of the Healthcare sector rather than any layer of the AI build-out. Quest holds a seat in the S&P 500 but none in our index, and it carries no Closelooknet score. The one quote that names 'DGX' in the diary refers to Nvidia's DGX Cloud product, not to Quest Diagnostics, so it is a ticker coincidence rather than coverage of the company.

Does Quest Diagnostics Incorporated pay a dividend?

Quest Diagnostics Incorporated has paid 3.32 USD per share over the last twelve months, paid quarterly, a trailing yield of 1.40% on the 2026-09-25 close; the last distribution recorded in the price series was 0.86 USD on 2026-07-08. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Quest Diagnostics Incorporated recently?

The most recent analyst action on Quest Diagnostics Incorporated on the Closelooknet wire is a price target by Truist on 2026-09-21 (target 260 from 250). 2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for DGX, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Diagnostics & Research. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.